AGEN stock forecast
Our latest prediction for Agenus, Inc.'s stock price was made on the April 12, 2017 when the stock price was at 3.24$.
In the short term (2weeks), AGEN's stock price should outperform the market by 5.28%. During that period the price should oscillate between -7.67% and +12.76%.
In the medium term (3months), AGEN's stock price should outperform the market by 10.40%. During that period the price should oscillate between -20.08% and +35.71%.Get email alerts
About Agenus, Inc.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
At the moment the company generates 39M USD in revenues.
On its last earning announcement, the company reported a loss of -1.39$ per share.
The book value per share is -0.99$
Three months stock forecastApril 12, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|